PhytoHealth
PhytoHealth (TWSE: 4108) is a Taiwan-listed botanical drug company that develops plant-based pharmaceuticals using purified Astragalus polysaccharide technology, with lead product PG2 being the world's only approved prescription treatment for cancer-related fatigue and NHI-reimbursed in Taiwan.
- Company typePublic
- Founded1998
- HeadquartersTaipei, Taiwan
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What PhytoHealth does
PhytoHealth (懷特生技新藥, TWSE: 4108) is a Taiwan-based botanical pharmaceutical company founded in 1998 and recognized as Taiwan's first listed new drug R&D company. The company operates as part of the Mayo-PhytoHealth-Anke BioTech Group (美吾華·懷特·安克生技集團) and develops proprietary plant-derived drugs using a disease-targeted methodology built around purified Astragalus polysaccharide (PG2 / 精製黃耆多醣) extracts. Its flagship commercial product, PhytoHealth Blood Treasure (PG2 / 懷特血寶), is the world's only approved prescription drug for cancer-related fatigue (CRF) — an ICD-10 classified condition — and was Taiwan's first TFDA-approved botanical new drug, listed on National Health Insurance (NHI) reimbursement since March 2021 for advanced breast cancer patients.
The company operates across three product layers: (1) prescription pharmaceuticals — PG2 for cancer-related fatigue and Oraphine (懷特痛寶), a nalbuphine oral capsule for moderate-to-severe acute pain with low addiction and low respiratory depression profile; (2) a pipeline of US FDA Phase IIa-completed botanical drug candidates — PhytoHealth Bone Treasure (懷特骨寶) for bone disease and PhytoHealth Sugar Treasure (懷特糖寶) for diabetic kidney disease; and (3) a portfolio of health supplements (PhytoHealth Qi-Li, An-Su, Huang-Qi-Yin) leveraging the same Astragalus polysaccharide platform for post-cancer care and consumer wellness markets. The business model combines direct hospital sales with NHI reimbursement for volume-driven adoption in Taiwan and self-pay channels for expanded indications and international markets, supplemented by an emerging licensing and co-development pathway for international expansion. Leadership is headed by Chairman and CEO Lee Yi-Chi (李伊俐) with four independent directors including Audit Committee convener Lin Shui-Long (林水龍).
PhytoHealth firmographics
Firmographics- Name
- PhytoHealth
- Legal name
- 懷特生技新藥股份有限公司
- Website
- https://phytohealth.com.tw
- Company type
- Public
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PhytoHealth (TWSE: 4108) is a Taiwan-listed botanical drug company that develops plant-based pharmaceuticals using purified Astragalus polysaccharide technology, with lead product PG2 being the world's only approved prescription treatment for cancer-related fatigue and NHI-reimbursed in Taiwan.
- Ownership category
- akta.pro rank
PhytoHealth industry classification
Industry- Product category
- Botanical Pharmaceuticals
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)
- akta.pro secondary industries
- Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD), Herbal & Botanical Supplements (CRADAGAD)
Keywords
Where PhytoHealth is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices1 record
Markets served
PhytoHealth business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Revenue from prescription pharmaceutical products including PhytoHealth Blood Treasure (PG2) for cancer-related fatigue and Oraphine for pain management, sold through hospital channels with NHI reimbursement in Taiwan and self-pay expansion internationally.
- Health Supplement Products: Revenue from functional health food products developed using proprietary botanical technology, positioned as post-cancer care and wellness market expansion.
- Licensing and Technology Transfer: Potential revenue from out-licensing products and co-development partnerships, including product/project licensing of PhytoHealth Blood Treasure, Pain Relief, Bone Protection, and Sugar Protection to international partners.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | NHI Reimbursed Cancer Fatigue Treatment |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
PhytoHealth product offering
Product offeringCore offering
PhytoHealth is a Taiwan-based pharmaceutical company that develops and commercializes disease-targeted botanical (plant-based) new drugs derived from purified Astragalus polysaccharide (PG2). Its two commercialized products are PhytoHealth Blood Treasure (PG2) lyophilized injection for cancer-related fatigue—the world's only approved prescription treatment for CRF and Taiwan's first TFDA-approved botanical new drug—and Oraphine (nalbuphine) soft capsule for post-surgical acute pain with low addiction profile. The company also sells health supplements and has pipeline candidates for bone disease and diabetic kidney disease.
Product overview
PhytoHealth (懷特生技新藥) is Taiwan's first listed botanical new drug R&D company. The company operates two commercialized core drugs (懷特血寶® for cancer-related fatigue and 懷特痛寶® for pain management) and a pipeline of investigational botanical drugs (懷特骨寶® and 懷特糖寶®) targeting bone health and diabetic kidney disease respectively. The product portfolio spans prescription pharmaceutical drugs, over-the-counter health supplements (懷特耆力®, 懷特胺速®, 懷特皇耆飲®), and a dedicated R&D center for purified Astragalus polysaccharide technology. The company leverages its disease-targeted plant drug development model, validated by TFDA's first botanical new drug approval for 懷特血寶®.
Differentiator
Problem solved
Functional benefit
Brands
- 懷特血寶: PG2, a plant-based new drug for Cancer-Related Fatigue (CRF). Taiwan's first TFDA-approved botanical new drug. Used for cancer-related fatigue in cancer patients.
- 懷特痛寶 (Oraphine)
- 懷特骨寶
- 懷特糖寶
- 懷特耆力
- 懷特胺速
- 懷特皇耆飲
- 精製黃耆多醣
Products and services
- PhytoHealth Blood Treasure (PG2) Lyophilized Injection (懷特血寶®凍晶注射劑) The world's first and only approved prescription drug for Cancer-Related Fatigue (CRF), extracted from Astragalus (黃耆). Taiwan TFDA's first botanical new drug approval, with 15 years of clinical evidence and listed as first-line standard treatment for moderate-to-severe cancer fatigue. Covered under Taiwan NHI reimbursement for advanced breast cancer patients. Real-world evidence shows 91% patient improvement rate.
- Oraphine Soft Capsule (懷特痛寶®軟膠囊)
Quantifiable outcome
- 91% patient improvement rate in cancer fatigue symptoms
- +5 more outcomes
Companies that use PhytoHealth
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
PhytoHealth technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
PhytoHealth partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship and core.
- Aristro Pharma (Germany)flagshipPartnership with German pharmaceutical company Aristro Pharma for regulatory registration and distribution of Oraphine (pain medication) in Germany. Letter of Intent signed in Q1 2025 with regulatory registration planned for Q4 2025, targeting the approximately USD 200 million German pain medication market.
- Indena S.p.A.corePartnership with Italian phytochemical raw materials manufacturer Indena for joint development of botanical raw materials. Indena will assist with regulatory registration and EU market sales for botanical products. Indena is a century-old professional botanical extraction company and the primary raw material supplier for Paclitaxel, the most widely used cancer drug globally, with 4 production bases and business in 80+ countries.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
PhytoHealth competitors and assessment
Company assessmentRegional players
- TaiGen Biotechnology: Taiwan-listed biopharma developing novel therapeutics with both domestic commercialization and international out-licensing strategy. Comparable as an Asia-listed R&D pharma with hospital-channel distribution and pipeline-driven growth model.
- Yung Shin Pharmaceutical: Taiwan-based pharmaceutical company developing and commercializing specialty drugs including oncology supportive care. Comparable as a Taiwan public pharma with similar hospital-channel distribution and NHI reimbursement model.
- PharmaEngine: Taiwan-listed (TPEx) specialty pharma focused on oncology drug development and licensing. Comparable as a Taiwan-headquartered public pharma developing novel cancer therapeutics with international partnership-driven commercialization strategy.
Direct peers
- Kunming Pharmaceutical: China-based botanical pharmaceutical company developing plant-derived drugs for oncology and supportive care. Comparable as an Asia-rooted botanical pharma R&D company with traditional medicine-based commercialized products.
- Hutchison China MediTech (HUTCHMED): China-rooted pharmaceutical company that develops botanical-derived and targeted oncology therapies, including compounds for cancer-related indications. Highly comparable as an Asia-listed R&D pharma commercializing novel oncology and supportive care drugs globally.
- Yiling Pharmaceutical: China-based pharmaceutical company focused on traditional Chinese medicine-derived (botanical) prescription drugs. Directly comparable business model of commercializing clinically validated botanical pharmaceutical products, with similar Astragalus and herbal product portfolios.
- Tsumura & Co. Japan-listed pharmaceutical company specializing in Kampo (traditional herbal) prescription medicines with clinical evidence base. Comparable as an Asia-listed botanical prescription pharma with hospital prescription channel and reimbursement-based model.
Others
- Indena S.p.A. Italy-based century-old botanical extraction and ingredient manufacturer; PhytoHealth's EU partner. Comparable as a botanical/phytopharmaceutical specialist working in the same plant-derived active ingredient and finished product value chain.
Broad incumbents
- Helsinn Group: Swiss specialty pharma focused on cancer supportive care and gastrointestinal products. Comparable as a cancer-related supportive care pharmaceutical company with hospital-channel distribution in similar oncology quality-of-life therapeutic areas.
- AMAG Pharmaceuticals (now part of Covis Pharma): Specialty pharma historically focused on cancer-related fatigue, postpartum hemorrhage, and supportive care. Comparable as a player in cancer-related fatigue supportive care, which directly overlaps PhytoHealth's core PG2 indication.
Market position
Strengths5 records
Weaknesses1 record
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
PhytoHealth social profiles
Digital presencePhytoHealth financial estimates
Financial estimateRevenue estimate
Valuation estimate
PhytoHealth leadership team
Management profileNumber of profiles
Profiles7 records
PhytoHealth funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PhytoHealth M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PhytoHealth
What does PhytoHealth do?
PhytoHealth is a Taiwan-based pharmaceutical company that develops and commercializes disease-targeted botanical (plant-based) new drugs derived from purified Astragalus polysaccharide (PG2). Its two commercialized products are PhytoHealth Blood Treasure (PG2) lyophilized injection for cancer-related fatigue—the world's only approved prescription treatment for CRF and Taiwan's first TFDA-approved botanical new drug—and Oraphine (nalbuphine) soft capsule for post-surgical acute pain with low addiction profile. The company also sells health supplements and has pipeline candidates for bone disease and diabetic kidney disease.
Is PhytoHealth a public or private company?
PhytoHealth is a public company. It is classified as public and is currently operating.
When was PhytoHealth founded?
PhytoHealth was founded in 1998. It employs 1 to 10 people.
Where is PhytoHealth based?
PhytoHealth is headquartered in Taipei, Taiwan, in the Asia region.
How does PhytoHealth make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are health Supplement Products and licensing and Technology Transfer.
Who are PhytoHealth's main competitors?
Regional players on record are TaiGen Biotechnology, Yung Shin Pharmaceutical and PharmaEngine. Direct peers are Kunming Pharmaceutical, Hutchison China MediTech (HUTCHMED), Yiling Pharmaceutical and Tsumura & Co.. Indena S.p.A. is listed as an others. Broad incumbents are Helsinn Group and AMAG Pharmaceuticals (now part of Covis Pharma).
Does PhytoHealth have an API?
No public API is recorded for PhytoHealth.
What industry is PhytoHealth in?
PhytoHealth's product category is Botanical Pharmaceuticals. Its primary akta.pro industry code is EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives, with a secondary code of AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts). Its NAICS code is 325411 and its SIC code is 2833.